Literature DB >> 35587290

Treatment and secondary prophylaxis of venous thromboembolism in cancer patients.

Nadeen T Ali1,2, Annie Young3.   

Abstract

Cancer-associated thrombosis (CAT) adversely affects the quality of life and survival of people with cancer. A holistic approach is optimal for the treatment and secondary prophylaxis of venous thromboembolism (VTE) including shared decision-making around anticoagulation, considering individual risk factors for VTE recurrence, morbidities from VTE, and resources available in cancer centres around the world. Taking a global perspective on availability and cost, this paper guides the reader through the wider aspects of treatment and secondary thromboprophylaxis which, in turn, influence the recent international guidelines.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cancer-associated thrombosis; Direct oral anticoagulant; Low-molecular-weight heparin; Treatment and secondary thromboprophylaxis

Mesh：

Substances：

Year:  2022        PMID： 35587290     DOI： 10.1007/s00520-022-07135-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.359


  39 in total

1.  A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.

Authors:  Ingrid Pabinger; Nick van Es; Georg Heinze; Florian Posch; Julia Riedl; Eva-Maria Reitter; Marcello Di Nisio; Gabriela Cesarman-Maus; Noémie Kraaijpoel; Christoph Carl Zielinski; Harry Roger Büller; Cihan Ay
Journal:  Lancet Haematol       Date:  2018-06-07       Impact factor: 18.959

2.  Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.

Authors:  Mariasanta Napolitano; Giorgia Saccullo; Alessandra Malato; Delia Sprini; Walter Ageno; Davide Imberti; Doris Mascheroni; Eugenio Bucherini; Pina Gallucci; Andrea D'Alessio; Tullia Prantera; Pietro Spadaro; Stefano Rotondo; Pierpaolo Di Micco; Vincenzo Oriana; Oreste Urbano; Francesco Recchia; Angelo Ghirarduzzi; Lucio Lo Coco; Salvatrice Mancuso; Alessandra Casuccio; Giovam Battista Rini; Sergio Siragusa
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

3.  Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study.

Authors:  Cheng E Chee; Aneel A Ashrani; Randolph S Marks; Tanya M Petterson; Kent R Bailey; L Joseph Melton; John A Heit
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

4.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

5.  A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer.

Authors:  Alym Abdulla; Wendy M Davis; Namali Ratnaweera; Elena Szefer; Brooke Ballantyne Scott; Agnes Y Y Lee
Journal:  Thromb Haemost       Date:  2020-04-14       Impact factor: 5.249

6.  Risk factors for chronic thromboembolic pulmonary hypertension.

Authors:  D Bonderman; H Wilkens; S Wakounig; H-J Schäfers; P Jansa; J Lindner; I Simkova; A M Martischnig; J Dudczak; R Sadushi; N Skoro-Sajer; W Klepetko; I M Lang
Journal:  Eur Respir J       Date:  2008-09-17       Impact factor: 16.671

Review 7.  Venous thromboembolism: risk factors for recurrence.

Authors:  Tienan Zhu; Isabelle Martinez; Joseph Emmerich
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03       Impact factor: 8.311

8.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

9.  The incidence of cancer-associated thrombosis is increasing over time.

Authors:  Anjlee Mahajan; Ann Brunson; Oyebimpe Adesina; Theresa H M Keegan; Ted Wun
Journal:  Blood Adv       Date:  2022-01-11

10.  The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.

Authors:  Frits I Mulder; Matteo Candeloro; Pieter W Kamphuisen; Marcello Di Nisio; Patrick M Bossuyt; Noori Guman; Kirsten Smit; Harry R Büller; Nick van Es
Journal:  Haematologica       Date:  2019-01-03       Impact factor: 11.047
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.